Using vaccine challenge model of T. gondii infection, we found that treatments with two commonly 23 used for NK cell depletion antibodies resulted in different survival outcomes during secondary 24 infection. Anti-ASGM1 resulted in 100% death and greater parasite burden at the site of infection 25 than anti-NK1.1. Anti-NK1.1 treatment resulted in increased parasite burdens, but animals did not 26 die. Further we found that anti-ASGM1 treatment depleted T cells. CD8+ T cells were more 27 susceptible that CD4+ T cells to the treatment. ASGM1 was expressed on a higher percentage of 28 is not an optimal choice for targeting only NK cells and more precise approaches should be used. 37
Introduction 41
T. gondii is an obligate intracellular protozoan that infects ~25-30% of people worldwide 42 (Flegr et al., 2014, Jones and Dubey, 2012) . Infection with the parasite in people is one of the leading 43 causes of foodborne illnesses in the U.S. resulting in hospitalization (Scallan et al., 2011) . Despite 44 induction of a robust CD8+ T cell response, the parasite does not get completely cleared and 45 during anti-ASGM1 treatment upon secondary T. gondii infection could be associated with the 165 depletion of CD8+ and CD4+ T cells. 166
167

ASGM1 is differentially expressed on CD8+ and CD4+ T cells in T. gondii immunized mice 168
The previous result showed that anti-ASGM1 treatment depleted CD8+ and CD4+ T cells 169 with potentially CD8+ T cells being targeted more than CD4+ T cells. Previous studies indicate that 170 CD8+ and CD4+ T cells have higher levels of ASGM1 on their surface after viral infections (Slifka 171 et al., 2000 , Moore et al., 2008 possibly making them susceptible to anti-ASGM1 depletion. 172 Therefore, we measured by flow cytometry whether ASGM1 was expressed on CD8+ and CD4+ T 173 cells after T. gondii-immunization in mice and how ASGM1 levels changed on T cells after challenge 174 infection. ASGM1 was detected on both cell types in immunized mice ( Fig. 3A-F) . After secondary 175 parasite infection, the frequency and number of ASGM1+ CD4+ T cells and number of ASGM1+ 176
CD8+ T cells increased at the challenge site (Fig. 3C-E). The frequency of ASGM1+ CD8+ T cells in 177
peritoneum and spleen did not increase ( Fig. 3 A-D) . Interestingly, ASGM1 was expressed on a 178 much higher percentage of CD8+ T cells than CD4+ T cells in both PEC and spleen. 179 180
Anti-ASGM1 treatment depletes effector and effector memory CD8+ T cell subsets 181
Previous studies reported that ASGM1 was differentially enriched among different CD8+ T 182 cell subsets. In naïve unimmunized mice central memory phenotype (CD44 high , CD62L+, CCR7+ and 183 CD122+) CD8+ T cells expressed more ASGM1 + than other T cell subsets (Kosaka et al., 2006 , 184 Kosaka et al., 2007 . Since the mice in our studies were immunized and the protection was lost when 185 the animals were treated with anti-ASGM1, this could suggest that ASGM1 might be enriched on T. 186 gondii specific memory T cell populations. Therefore, we next determined whether ASGM1 was 187 expressed on certain subsets of CD8+ T cells and whether these same subsets were preferentiallyabsence or presence of RH infection and T cell phenotype was assayed based on the expression of 190 CD44, a marker of antigen-experienced T cells (Budd et al., 1987) and CD62L, a marker of cells that 191 home to lymph nodes (Lefrancois, 2006) . In CPS-immunized mice CD8+ T cells were distributed 192 between Tcm (central memory, CD44+CD62L+) > Tn (naïve, CD44-CD62L+) > Tem (effector 193 memory, CD44+CD62L-) > Tef (effector, CD44-CD62L-) (Fig. 4A) (Srivastava et al., 2018) . 194 ASGM1 was mainly expressed on antigen-experienced CD44
high Tcm and Tem CD8+ T cells in CPS 195 immunized mice (Fig. 4B) . After infection of CPS-immunized mice with RH, ASGM1 was also 196 expressed on Tef and Tn CD8+ T cells (Fig. 4B) . Anti-ASGM1 reduced the frequency of all of the 197 CD8+ T cell subsets in CPS-immunized animals without RH challenge, except for the Tn subset, 198 which increased after the depletion. After RH challenge, there was an expected increase in Tef. (Fig. 4C) . Anti-ASGM1 also depleted these cells during 210 secondary RH infection. Similarly to the previously observed increase in naïve CD8+ T cells, non-T. 211 gondii specific CD11a-CD49d-CD8+ T cells increased after the depletion. In accordance to the 212 depletion effect of anti-ASGM1, CD11a+CD49d+ CD8+ T cells were highly enriched in ASGM1suggested that ASGM1 is enriched on T. gondii-specific CD8+ T cells and these cells were depleted
Anti-ASGM1 treatment depletes activated CD8+ and CD4+ T cells 218
The above data identified that ASGM1 was expressed on a majority of CD8+ T cells that 219 expressed surrogate markers of T. gondii specificity (CD11a and CD49d) and effector CD8+ T cells 220 were depleted the most by anti-ASGM1 treatment. One study showed that ASGM1+ CD8+ T cells 221 produced more IFNγ than ASGM1-CD8+ T cells upon stimulation with IL-12 (+IL-2) in vitro 222 (Kosaka et al., 2006) . IL-12 is produced after T. gondii infection and is essential for protection via 223 induction of IFNγ (Gazzinelli et al., 1993 , Hunter et al., 1995b , Yap et al., 2000 . To find whether the 224 increased susceptibility to the secondary infection during anti-ASGM1 treatment could be associated 225 with the depletion of IFNγ-producing T cells, CPS-immunized mice were challenged with RH and 226 their CD8+ and CD4+ T cell functionality was assessed after treatment with ani-ASGM1 compared 227 to non-treated controls. Peritoneal CD8+ T cells were stimulated with TLA ( Fig. 5A-B Anti-ASGM1 treatment during reinfection increased the rate of mouse death and depleted 239 IFNγ+ CD8+ and CD4+ T cells. To address whether the lethal effect of the antibody could be 240 counterbalanced by IFNγ supplementation, recombinant IFNγ was administered during anti-ASGM1 241 treatment of CPS-immunized and RH infected mice. The cytokine supplementation had a therapeutic 242 effect and significantly prolonged the survival of anti-ASGM1 treated mice (Fig. 6) . Therefore, the 243 detrimental effect of anti-ASGM1 treatment on the health and survival of mice could be associated 244 with the depletion of IFNγ-producing CD8+ and CD4+ T cells in addition to IFNγ-producing NK 245 cells. 246 of ASGM1 expression on T cells could provide the cues on its functional importance and reveal its 296 potential in use for immunotherapies. 297
CD4+ T cells were negatively affected by anti-ASGM1 treatment of T. gondii-immunized 298
mice. In addition to CD8+ T cells, total splenic and IFNγ-producing peritoneal CD4+ T cells were 299 reduced after the treatment. This is in accordance to an early study on NK cell role in protection 300 against T. gondii reinfection in the absence of CD8+ T cells (Denkers et al., 1993) . T. gondii-301 immunized CD8+ T cell deficient mice (β2m-/-) survived lethal reinfection and died after anti-NK1.1 302 or anti-ASGM1 treatments. Interestingly, mice died faster after anti-ASGM1 treatment as compared 303 to anti-NK1.1. This result implied that these treatments could have different effects on the cells other 304 than CD8+ T cells and NK cells, potentially CD4+ T cells (Denkers et al., 1993) . 305
The functional role of ASGM1-mediated signaling in T cells is not known. One possibility is 306 that ASGM1 could be functionally relevant for T cell biology as a part of lipid rafts. ASGM1 is a 307 glycolipid that is enriched in lipid rafts, small dynamic ordered domains that compartmentalize 308 cellular processes (Pike, 2006) . Upon T cell activation, TCR engagement leads to an aggregation of 309 these domains (Dinic et al., 2015) . This aggregation then facilitates TCR signaling by bringing 310 molecules needed for TCR closer to each other. It was found earlier that engagement of GM1 by 311 cholera toxin leads to an activation of T cells (Janes et al., 1999) . ASGM1 is a derivative of GM1 and 312 colocalizes with GM1 in the lipid rafts on T cells (Moore et al., 2008) . ASGM1 could also be 313 involved in TCR signaling and T cell activation. Whether the presence and quantity of ASGM1 in 314 lipid rafts affects T cell functionality is not known. In addition, whether T cells with enriched 315 ASGM1 lipid raft content have a superior ability for TCR signaling and activation as compared to 316 ASGM1 negative T cells remains to be investigated. That would be important to address as it could 317 be useful for the future design of T cell-based immunotherapies. 318
As a further point, the presence of ASGM1 could be advantageous for T cell survival duringstructures for binding and recognition (Schwegmann-Wessels et al., 2011 , Neu et al., 2011 . 322
Apicomplexan parasites, including T. gondii and Plasmodium falciparum, also employ recognition of 323 sialic acids as part of interactions with the hosts (Monteiro et al., 1998 , Blumenschein et al., 2007 Gaur and Chitnis, 2011). The T. gondii microneme proteins bind to sialylated glycoconjugates on 325 host cells and facilitate invasion (Blumenschein et al., 2007 , Friedrich et al., 2010 . As any other 326 nucleated cells, T cells can get T. gondii-infected and killed by parasites or lymphocytes. Therefore, 327 one possible mechanism by which ASGM1+ CD8+ T cells could have an advantage in survival over 328
ASGM1-CD8+ cells during T. gondii infection could be their reduced sialic acid content and thus 329 resistance to being infected by the parasites. 330
In summary, our data showed that anti-ASGM1 antibody treatment is not a specific approach 331 to study the role of NK cells during T. gondii infection. This method could be informative when used 332 with caution and in combination with other NK cell specific methods. We demonstrated that in T. The log-rank (Mantel-Cox) test was used to evaluate survival rates, **p<0.01. 
